NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
NITRO-DUR (nitroglycerin) by Pfizer is clinical pharmacology the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. First approved in 1985.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITRO-DUR is a transdermal extended-release nitroglycerin patch used to prevent and treat angina pectoris. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins, and reducing cardiac preload and afterload. The drug has been a cornerstone of angina management since FDA approval in 1985.
$0.003BPart D
LOE ApproachingAs LOE approaches, the brand team is likely focused on lifecycle extension, partnership development, and transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…
Worked on NITRO-DUR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.